Chinese-made antibody-drug conjugates (ADCs) are poised to come from behind as fast-followers of their global peers on the back of impressive new Phase I and II clinical data to be orally reported at the European Society for Medical Oncology (ESMO) Congress, being held in Madrid, Spain over 20-24 October.
Key Takeaways
-
Kelun/Merck, Hansoh's ADCs, targeting Trop2 and B7-H4 respectively, shine at ESMO with impressive early-stage clinical outcomes versus global front-runners.
Breast cancer has emerged as one of the main areas of focus.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?